Nebivor (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivor, is a beta‑blocker presented as a tablet for oral use. It treats essential hypertension and heart failure in adult patients. GNH USA supplies Nebivor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivor (nebivolol) is used in cardiovascular therapy to manage blood pressure and heart function.

Essential hypertension: lowers systolic and diastolic blood pressure to target levels. Heart failure: improves cardiac output and reduces risk of hospitalization. Elevated blood pressure in patients with comorbid conditions: helps achieve recommended blood‑pressure goals.

Nebivor may cause a range of adverse reactions. Monitoring and patient education are recommended.

Common Side Effects: - Headache - Dizziness - Fatigue - Nasal congestion - Nausea

Serious or Rare Side Effects: - Severe bradycardia - Marked hypotension - Bronchospasm in susceptible individuals - Atrioventricular block - Allergic reactions such as rash or angioedema

Nebivor requires careful assessment before and during therapy.

Cardiovascular assessment: evaluate heart rate and blood pressure prior to initiation. Asthma or COPD: use with caution due to potential bronchoconstriction. Diabetes monitoring: β‑blockade may mask hypoglycaemic symptoms. Renal impairment: consider dose adjustment in reduced clearance. Concomitant AV‑nodal blockers: increased risk of bradycardia. Store at ambient temperature: keep below 25°C, protect from moisture and light.

Nebivor can interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Non‑selective β‑blockers: additive bradycardia. - Calcium channel blockers (verapamil, diltiazem): risk of severe AV block. - Clonidine: possible rebound hypertension on abrupt discontinuation. - Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: additive hypotensive effect. - Diuretics: potential electrolyte disturbances. - SSRIs or other antidepressants: may increase bradycardia risk.